Skip to main content

Table 1 Patient characteristics and association of CD8+ cells (intra- and peri-tumoral) with clinicopathological data (max n = 130)

From: CD8/CD45RO T-cell infiltration in endoscopic biopsies of colorectal cancer predicts nodal metastasis and survival

Feature

  

CD8i N (%)

CD8s N (%)

  
  

N (%)

Low

High

P-value

Low

High

P-value

Age (years) (n = 130)

Median (min, max)

72 (30-91)

71.4 (30-91)

73.8 (50-90)

0.3872

72.4 (30-91)

71 (30-90)

0.876

Gender (n = 130)

Male

80 (61.5)

61 (61.0)

19 (63.3)

1.0

40 (61.5)

40 (61.5)

1.0

 

Female

50 (38.5)

39 (39.0)

11 (36.7)

 

25 (38.5)

25 (38.5)

 

Histological subtype (n = 130)

Non-mucinous

106 (81.5)

80 (80.0)

26 (86.7)

0.5923

49 (75.4)

57 (87.7)

0.1123

 

Mucinous

24 (18.5)

20 (20.0)

4 (13.3)

 

16 (24.6)

8 (12.3)

 

Tumour location (n = 129)

Left

43 (33.3)

33 (33.3)

10 (33.3)

0.8606

21 (32.3)

22 (34.4)

0.7333

 

Rectum

30 (23.3)

22 (22.2)

8 (26.7)

 

17 (26.2)

13 (20.3)

 
 

Right

56 (43.4)

44 (44.4)

12 (40.0)

 

27 (41.5)

29 (45.3)

 

pT (n = 130)

pT1 + pT2

30 (23.1)

15 (15.0)

15 (50.0)

<0.0001

12 (18.5)

18 (27.7)

0.2979

 

pT3 + pT4

100 (76.9)

85 (85.0)

15 (50.0)

 

53 (81.5)

47 (72.3)

 

pN (n = 130)

pN0

54 (41.5)

34 (34.0)

20 (66.7)

0.0015

26 (40.0)

28 (43.1)

0.8588

 

pN1-2

76 (58.5)

66 (66.0)

10 (33.3)

 

39 (60.0)

37 (56.9)

 

cT (n = 30)

cT1-2

9 (31.0)

6 (27.3)

3 (42.9)

0.6424

5 (45.5)

4 (22.2)

0.2371

 

cT3-4

20 (69.0)

16 (72.7)

4 (57.1)

 

6 (54.6)

14 (77.8)

 

cN (n = 113)

cN0

68 (62.4)

50 (59.5)

18 (72.0)

0.2583

32 (57.1)

36 (67.9)

0.3229

 

cN1-2

41 (37.6)

34 (40.5)

7 (28.0)

 

24 (42.9)

17 (32.1)

 

No. LN collected (n = 130)

Median (min, max)

22 (4-73)

23.0 (6-67)

16.5 (4-73)

0.0842

23.0 (4-67)

18 (6-73)

0.1369

Tumour deposits (n = 108)

0

91 (84.3)

67 (79.8)

24 (100.0)

0.0117

42 (82.4)

49 (86.0)

0.792

 

≥1

17 (15.7)

17 (20.2)

0 (0.0)

 

9 (17.7)

8 (14.0)

 

Metastasis (n = 123)

cM0

86 (69.9)

63 (67.0)

23 (79.3)

0.2519

42 (68.8)

44 (71.0)

0.8457

 

cM1

37 (30.1)

31 (33.0)

6 (20.7)

 

19 (31.2)

18 (29.0)

 

Lymphatic invasion (n = 113)

L0

29 (25.7)

17 (19.3)

12 (48.0)

0.008

10 (18.5)

19 (32.2)

0.1312

 

L1

84 (74.3)

71 (80.7)

13 (53.0)

 

44 (81.5)

40 (67.8)

 

Venous invasion (n = 114)

V0

57 (50.0)

39 (44.3)

18 (69.2)

0.0433

26 (47.3)

31 (52.5)

0.708

 

V1-2

57 (50.0)

49 (55.7)

8 (30.8)

 

29 (52.7)

28 (47.5)

 

Perineural invasion (n = 111)

Pn0

100 (90.1)

75 (87.2)

25 (100.0)

0.0671

48 (90.6)

52 (89.7)

1.0

 

Pn1

11 (9.1)

11 (12.8)

0 (0.0)

 

5 (9.4)

6 (10.3)

 

Tumour grade (n = 130)

G1-2

85 (65.4)

66 (66.0)

19 (63.3)

0.8286

40 (61.5)

45 (69.2)

0.3566

 

G3

45 (34.6)

34 (34.0)

11 (36.7)

 

25 (38.5)

20 (30.8)

 

Postoperative therapy (n = 127)

None

88 (69.3)

65 (66.3)

23 (79.3)

0.2524

41 (64.1)

47 (74.6)

0.2491

 

Yes

39 (30.7)

33 (33.7)

6 (20.7)

 

23 (36.0)

16 (25.4)

 

MMR status (n = 117)

Proficient

99 (84.6)

77 (85.6)

22 (81.5)

0.5596

52 (89.7)

47 (79.7)

0.1996

 

Deficient

18 (15.4)

13 (14.4)

5 (18.5)

 

6 (10.3)

12 (20.3)

 

Survival time (n = 76)

Median (95% CI) months

73.5 (29-105)

53.1 (22.6-73.9)

Not reached

0.0026

26.4 (13.7-73.5)

105.4 (54.9-NE)

0.0053